Low dose of aspirin reduces Alzheimer’s protein amyloid in mice
By Alice Tuohy | Monday 02 July 2018
JNeurosci: Aspirin induces Lysosomal biogenesis and attenuates Amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPARα
Scientists in the US have found that a low dose of aspirin reduces the hallmark Alzheimer’s protein, amyloid, in the brains of mice with features of the disease. The findings are published today (Monday 2 July) in the scientific publication, JNeurosci.
Dr Sara Imarisio, Head of Research of Alzheimer’s Research UK, said:
“Aspirin is a commonly taken medicine for a number of health conditions, but there has been little research to examine potential benefits for Alzheimer’s disease. This early-stage research suggests aspirin may help improve how the brain removes amyloid, a protein known to build up in Alzheimer’s. The study reveals important insights into the mechanisms through which aspirin may impact brain health, however this is a small study in mice so it’s too early to draw conclusions about whether aspirin could be used to treat Alzheimer’s in people.
“Ultimately the only way to see whether aspirin could help treat Alzheimer’s disease is through large-scale, well-controlled clinical trials in people. Alzheimer’s Research UK is currently funding a study at the University of Oxford examining the effect of aspirin on memory and thinking in people at higher risk of dementia. In this study, aspirin is being investigated for its potential to reduce the risk of developing dementia, which could have a significant impact on healthy ageing.”